The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant: Post-Transplants Events
In this multicenter study, we assessed the use of palifermin (recombinant human–keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and acute GvHD (aGvHD) induced by a hematopoietic stem cell transplant (HSCT). Fifty-three patients with hematological diseases received three doses...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2007, Vol.40 (10), p.983-988 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 988 |
|---|---|
| container_issue | 10 |
| container_start_page | 983 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 40 |
| creator | Nasilowska-Adamska, B Rzepecki, P Manko, J Czyz, A Markiewicz, M Federowicz, I Tomaszewska, A Piatkowska-Jakubas, B Wrzesien-Kus, A Bieniaszewska, M Duda, D Szydlo, R Halaburda, K Szczepinski, A Lange, A Hellman, A Robak, T Skotnicki, A Jedrzejczak, W W Walewski, J Holowiecki, J Komarnicki, M Dmoszynska, A Warzocha, K Marianska, B |
| description | In this multicenter study, we assessed the use of palifermin (recombinant human–keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and acute GvHD (aGvHD) induced by a hematopoietic stem cell transplant (HSCT). Fifty-three patients with hematological diseases received three doses of palifermin (60
μ
g/kg once daily i.v.) pre- and post-conditioning regimens (total six doses). A retrospective control group of 53 transplant patients received no palifermin. There was a significant reduction in the incidence of OM of WHO (World Health Organization) grades 1–4 (58 vs 94%,
P |
| doi_str_mv | 10.1038/sj.bmt.1705846 |
| format | Article |
| fullrecord | <record><control><sourceid>springer</sourceid><recordid>TN_cdi_springer_journals_10_1038_sj_bmt_1705846</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1038_sj_bmt_1705846</sourcerecordid><originalsourceid>FETCH-springer_journals_10_1038_sj_bmt_17058463</originalsourceid><addsrcrecordid>eNqVkLtOxDAQRS0EEuHRUk8JxWYd8thQIxDStttbJpkkEzl25JksH8YPkpXyA1S3uPee4ij1lOk003m95zH9niTNDrqsi-pKJVlxqHZlXpXXKtGvVb3L8-rtVt0xj1pnRaHLRP2eBgTynVvQNwihg9k66jBO5OH5iDOd7Vq8QPAQonUwLU1gEmKwvgXbLILQR9sJnDHywjAEFmiJ0fKFvPKE0AvDD8kAA05Wggs9NStsmzEsvsXYB_L9tpgDoVADLDhBg86BROt5dtbLg7rprGN83PJe7T8_Tu9fO57jSsBoxrBEv1Ym0-bixvBoVjdmc5P___EHV650KA</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant: Post-Transplants Events</title><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Nasilowska-Adamska, B ; Rzepecki, P ; Manko, J ; Czyz, A ; Markiewicz, M ; Federowicz, I ; Tomaszewska, A ; Piatkowska-Jakubas, B ; Wrzesien-Kus, A ; Bieniaszewska, M ; Duda, D ; Szydlo, R ; Halaburda, K ; Szczepinski, A ; Lange, A ; Hellman, A ; Robak, T ; Skotnicki, A ; Jedrzejczak, W W ; Walewski, J ; Holowiecki, J ; Komarnicki, M ; Dmoszynska, A ; Warzocha, K ; Marianska, B</creator><creatorcontrib>Nasilowska-Adamska, B ; Rzepecki, P ; Manko, J ; Czyz, A ; Markiewicz, M ; Federowicz, I ; Tomaszewska, A ; Piatkowska-Jakubas, B ; Wrzesien-Kus, A ; Bieniaszewska, M ; Duda, D ; Szydlo, R ; Halaburda, K ; Szczepinski, A ; Lange, A ; Hellman, A ; Robak, T ; Skotnicki, A ; Jedrzejczak, W W ; Walewski, J ; Holowiecki, J ; Komarnicki, M ; Dmoszynska, A ; Warzocha, K ; Marianska, B</creatorcontrib><description><![CDATA[In this multicenter study, we assessed the use of palifermin (recombinant human–keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and acute GvHD (aGvHD) induced by a hematopoietic stem cell transplant (HSCT). Fifty-three patients with hematological diseases received three doses of palifermin (60
μ
g/kg once daily i.v.) pre- and post-conditioning regimens (total six doses). A retrospective control group of 53 transplant patients received no palifermin. There was a significant reduction in the incidence of OM of WHO (World Health Organization) grades 1–4 (58 vs 94%,
P
<0.001), 3–4 (13 vs 43%,
P
<0.001) and the median duration of OM (4 vs 9 days,
P
<0.001) in the palifermin group compared to the control group. The incidence of analgesics (32 vs 75.5%,
P
<0.001), opioid analgesics (24 vs 64%,
P
<0.001) and total parenteral nutrition (11 vs 45%,
P
<0.001) was also significantly reduced. The analysis of distribution of affected organs revealed that aGvHD was less prevalent in the palifermin group (
P
=0.036). There was no significant difference in the onset of any OM after HSCT, time to engraftment and length of hospitalization between groups. The drug was generally well tolerated and safe. Our results suggest that the use of palifermin reduces OM and probably aGvHD after HSCT, but a randomized trial is needed.]]></description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/sj.bmt.1705846</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Cell Biology ; Hematology ; Internal Medicine ; Medicine ; Medicine & Public Health ; original-article ; Public Health ; Stem Cells</subject><ispartof>Bone marrow transplantation (Basingstoke), 2007, Vol.40 (10), p.983-988</ispartof><rights>Springer Nature Limited 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/sj.bmt.1705846$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/sj.bmt.1705846$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,41486,42555,51317</link.rule.ids></links><search><creatorcontrib>Nasilowska-Adamska, B</creatorcontrib><creatorcontrib>Rzepecki, P</creatorcontrib><creatorcontrib>Manko, J</creatorcontrib><creatorcontrib>Czyz, A</creatorcontrib><creatorcontrib>Markiewicz, M</creatorcontrib><creatorcontrib>Federowicz, I</creatorcontrib><creatorcontrib>Tomaszewska, A</creatorcontrib><creatorcontrib>Piatkowska-Jakubas, B</creatorcontrib><creatorcontrib>Wrzesien-Kus, A</creatorcontrib><creatorcontrib>Bieniaszewska, M</creatorcontrib><creatorcontrib>Duda, D</creatorcontrib><creatorcontrib>Szydlo, R</creatorcontrib><creatorcontrib>Halaburda, K</creatorcontrib><creatorcontrib>Szczepinski, A</creatorcontrib><creatorcontrib>Lange, A</creatorcontrib><creatorcontrib>Hellman, A</creatorcontrib><creatorcontrib>Robak, T</creatorcontrib><creatorcontrib>Skotnicki, A</creatorcontrib><creatorcontrib>Jedrzejczak, W W</creatorcontrib><creatorcontrib>Walewski, J</creatorcontrib><creatorcontrib>Holowiecki, J</creatorcontrib><creatorcontrib>Komarnicki, M</creatorcontrib><creatorcontrib>Dmoszynska, A</creatorcontrib><creatorcontrib>Warzocha, K</creatorcontrib><creatorcontrib>Marianska, B</creatorcontrib><title>The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant: Post-Transplants Events</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><description><![CDATA[In this multicenter study, we assessed the use of palifermin (recombinant human–keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and acute GvHD (aGvHD) induced by a hematopoietic stem cell transplant (HSCT). Fifty-three patients with hematological diseases received three doses of palifermin (60
μ
g/kg once daily i.v.) pre- and post-conditioning regimens (total six doses). A retrospective control group of 53 transplant patients received no palifermin. There was a significant reduction in the incidence of OM of WHO (World Health Organization) grades 1–4 (58 vs 94%,
P
<0.001), 3–4 (13 vs 43%,
P
<0.001) and the median duration of OM (4 vs 9 days,
P
<0.001) in the palifermin group compared to the control group. The incidence of analgesics (32 vs 75.5%,
P
<0.001), opioid analgesics (24 vs 64%,
P
<0.001) and total parenteral nutrition (11 vs 45%,
P
<0.001) was also significantly reduced. The analysis of distribution of affected organs revealed that aGvHD was less prevalent in the palifermin group (
P
=0.036). There was no significant difference in the onset of any OM after HSCT, time to engraftment and length of hospitalization between groups. The drug was generally well tolerated and safe. Our results suggest that the use of palifermin reduces OM and probably aGvHD after HSCT, but a randomized trial is needed.]]></description><subject>Cell Biology</subject><subject>Hematology</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>original-article</subject><subject>Public Health</subject><subject>Stem Cells</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqVkLtOxDAQRS0EEuHRUk8JxWYd8thQIxDStttbJpkkEzl25JksH8YPkpXyA1S3uPee4ij1lOk003m95zH9niTNDrqsi-pKJVlxqHZlXpXXKtGvVb3L8-rtVt0xj1pnRaHLRP2eBgTynVvQNwihg9k66jBO5OH5iDOd7Vq8QPAQonUwLU1gEmKwvgXbLILQR9sJnDHywjAEFmiJ0fKFvPKE0AvDD8kAA05Wggs9NStsmzEsvsXYB_L9tpgDoVADLDhBg86BROt5dtbLg7rprGN83PJe7T8_Tu9fO57jSsBoxrBEv1Ym0-bixvBoVjdmc5P___EHV650KA</recordid><startdate>2007</startdate><enddate>2007</enddate><creator>Nasilowska-Adamska, B</creator><creator>Rzepecki, P</creator><creator>Manko, J</creator><creator>Czyz, A</creator><creator>Markiewicz, M</creator><creator>Federowicz, I</creator><creator>Tomaszewska, A</creator><creator>Piatkowska-Jakubas, B</creator><creator>Wrzesien-Kus, A</creator><creator>Bieniaszewska, M</creator><creator>Duda, D</creator><creator>Szydlo, R</creator><creator>Halaburda, K</creator><creator>Szczepinski, A</creator><creator>Lange, A</creator><creator>Hellman, A</creator><creator>Robak, T</creator><creator>Skotnicki, A</creator><creator>Jedrzejczak, W W</creator><creator>Walewski, J</creator><creator>Holowiecki, J</creator><creator>Komarnicki, M</creator><creator>Dmoszynska, A</creator><creator>Warzocha, K</creator><creator>Marianska, B</creator><general>Nature Publishing Group UK</general><scope/></search><sort><creationdate>2007</creationdate><title>The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant</title><author>Nasilowska-Adamska, B ; Rzepecki, P ; Manko, J ; Czyz, A ; Markiewicz, M ; Federowicz, I ; Tomaszewska, A ; Piatkowska-Jakubas, B ; Wrzesien-Kus, A ; Bieniaszewska, M ; Duda, D ; Szydlo, R ; Halaburda, K ; Szczepinski, A ; Lange, A ; Hellman, A ; Robak, T ; Skotnicki, A ; Jedrzejczak, W W ; Walewski, J ; Holowiecki, J ; Komarnicki, M ; Dmoszynska, A ; Warzocha, K ; Marianska, B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-springer_journals_10_1038_sj_bmt_17058463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Cell Biology</topic><topic>Hematology</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>original-article</topic><topic>Public Health</topic><topic>Stem Cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nasilowska-Adamska, B</creatorcontrib><creatorcontrib>Rzepecki, P</creatorcontrib><creatorcontrib>Manko, J</creatorcontrib><creatorcontrib>Czyz, A</creatorcontrib><creatorcontrib>Markiewicz, M</creatorcontrib><creatorcontrib>Federowicz, I</creatorcontrib><creatorcontrib>Tomaszewska, A</creatorcontrib><creatorcontrib>Piatkowska-Jakubas, B</creatorcontrib><creatorcontrib>Wrzesien-Kus, A</creatorcontrib><creatorcontrib>Bieniaszewska, M</creatorcontrib><creatorcontrib>Duda, D</creatorcontrib><creatorcontrib>Szydlo, R</creatorcontrib><creatorcontrib>Halaburda, K</creatorcontrib><creatorcontrib>Szczepinski, A</creatorcontrib><creatorcontrib>Lange, A</creatorcontrib><creatorcontrib>Hellman, A</creatorcontrib><creatorcontrib>Robak, T</creatorcontrib><creatorcontrib>Skotnicki, A</creatorcontrib><creatorcontrib>Jedrzejczak, W W</creatorcontrib><creatorcontrib>Walewski, J</creatorcontrib><creatorcontrib>Holowiecki, J</creatorcontrib><creatorcontrib>Komarnicki, M</creatorcontrib><creatorcontrib>Dmoszynska, A</creatorcontrib><creatorcontrib>Warzocha, K</creatorcontrib><creatorcontrib>Marianska, B</creatorcontrib><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nasilowska-Adamska, B</au><au>Rzepecki, P</au><au>Manko, J</au><au>Czyz, A</au><au>Markiewicz, M</au><au>Federowicz, I</au><au>Tomaszewska, A</au><au>Piatkowska-Jakubas, B</au><au>Wrzesien-Kus, A</au><au>Bieniaszewska, M</au><au>Duda, D</au><au>Szydlo, R</au><au>Halaburda, K</au><au>Szczepinski, A</au><au>Lange, A</au><au>Hellman, A</au><au>Robak, T</au><au>Skotnicki, A</au><au>Jedrzejczak, W W</au><au>Walewski, J</au><au>Holowiecki, J</au><au>Komarnicki, M</au><au>Dmoszynska, A</au><au>Warzocha, K</au><au>Marianska, B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant: Post-Transplants Events</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><date>2007</date><risdate>2007</risdate><volume>40</volume><issue>10</issue><spage>983</spage><epage>988</epage><pages>983-988</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><abstract><![CDATA[In this multicenter study, we assessed the use of palifermin (recombinant human–keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and acute GvHD (aGvHD) induced by a hematopoietic stem cell transplant (HSCT). Fifty-three patients with hematological diseases received three doses of palifermin (60
μ
g/kg once daily i.v.) pre- and post-conditioning regimens (total six doses). A retrospective control group of 53 transplant patients received no palifermin. There was a significant reduction in the incidence of OM of WHO (World Health Organization) grades 1–4 (58 vs 94%,
P
<0.001), 3–4 (13 vs 43%,
P
<0.001) and the median duration of OM (4 vs 9 days,
P
<0.001) in the palifermin group compared to the control group. The incidence of analgesics (32 vs 75.5%,
P
<0.001), opioid analgesics (24 vs 64%,
P
<0.001) and total parenteral nutrition (11 vs 45%,
P
<0.001) was also significantly reduced. The analysis of distribution of affected organs revealed that aGvHD was less prevalent in the palifermin group (
P
=0.036). There was no significant difference in the onset of any OM after HSCT, time to engraftment and length of hospitalization between groups. The drug was generally well tolerated and safe. Our results suggest that the use of palifermin reduces OM and probably aGvHD after HSCT, but a randomized trial is needed.]]></abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><doi>10.1038/sj.bmt.1705846</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2007, Vol.40 (10), p.983-988 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_springer_journals_10_1038_sj_bmt_1705846 |
| source | Nature; EZB-FREE-00999 freely available EZB journals; SpringerLink Journals - AutoHoldings |
| subjects | Cell Biology Hematology Internal Medicine Medicine Medicine & Public Health original-article Public Health Stem Cells |
| title | The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant: Post-Transplants Events |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T13%3A28%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-springer&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20influence%20of%20palifermin%20(Kepivance)%20on%20oral%20mucositis%20and%20acute%20graft%20versus%20host%20disease%20in%20patients%20with%20hematological%20diseases%20undergoing%20hematopoietic%20stem%20cell%20transplant:%20Post-Transplants%20Events&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Nasilowska-Adamska,%20B&rft.date=2007&rft.volume=40&rft.issue=10&rft.spage=983&rft.epage=988&rft.pages=983-988&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/sj.bmt.1705846&rft_dat=%3Cspringer%3E10_1038_sj_bmt_1705846%3C/springer%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |